Literature DB >> 7207202

Analysis of lipids and endothelial and smooth muscle cells of umbilical cord in familial homozygous hypercholesterolemia.

R E Ostlund, S V Hajek, R A Levy, J L Witztum.   

Abstract

Umbilical cord lipids from a familial hypercholesterolemia homozygote were extracted and quantitated. Free cholesterol was increased 26% and esterified cholesterol was increased 379% compared to normal, whereas phospholipid content was not altered. Analysis of homozygote umbilical artery revealed no excess cholesterol and the vessels were histologically normal. Thus, in the homozygote cord, accumulation of cholesterol occurs first in Wharton's jelly, the hypocellular glycosaminoglycan-enriched cord matrix. Skin fibroblasts, umbilical vein endothelial cells, and umbilical vein smooth muscle cells were cultured from the homozygote. Low density lipoprotein receptor activity was reduced to 9%-38% of normal in all cell types from the homozygote, demonstrating that vessel cells express the LDL, receptor defect seen in skin fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7207202     DOI: 10.1016/0026-0495(81)90153-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  The effects of amphotericin B on lipid metabolism in cultured human skin fibroblasts.

Authors:  R A Levy; R E Ostlund; J Brajtburg
Journal:  In Vitro Cell Dev Biol       Date:  1985-01

2.  Familial hypercholesterolemia. Evidence for a newly recognized mutation determining increased fibroblast receptor affinity but decreased capacity for low density lipoprotein in two siblings.

Authors:  R E Ostlund; R A Levy; J L Witztum; G Schonfeld
Journal:  J Clin Invest       Date:  1982-10       Impact factor: 14.808

3.  Diversity in expression of heterozygous familial hypercholesterolemia. Characterization of a unique kindred.

Authors:  R A Levy; R E Ostlund; C F Semenkovich; J L Witztum
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.